Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients

• Published in: British journal of clinical pharmacology Vol. 62; no. 1; pp. 81 - 96
• Main Authors: Perez‐Ruixo, Juan Jose, Piotrovskij, Vladimir, Zhang, Steven, Hayes, Siobhan, Porre, Peter De, Zannikos, Peter
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.07.2006; Blackwell Science; Blackwell Science Inc
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; anticancer drugs; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Biological and medical sciences; Biological Availability; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; farnesyltransferase inhibitor; Female; Humans; Infusions, Intravenous; Male; Medical sciences; Metabolic Clearance Rate; Middle Aged; Neoplasms - drug therapy; Neoplasms - metabolism; Original; Pharmacology. Drug treatments; population pharmacokinetics; Quinolones - administration & dosage; Quinolones - pharmacokinetics; Tablets; tipifarnib; Antineoplastic agent; Human; Drug; Population pharmacokinetics; Healthy subject; Enzyme; Transferases; farnesyltransferase inhibitor; Enzyme inhibitor; Tipifarnib; Malignant tumor; Farnesyl-diphosphate farnesyltransferase; anticancer drugs

Aims To characterize the population pharmacokinetics of tipifarnib. Methods A total of 1083 subjects treated orally with a solution, capsule or tablet formulations of tipifarnib, given as a single dose or as multiple twice‐daily doses (range 25–1300 mg) were combined with data from 1, 2 and 24 h int...